Replimune Sets Virtual Annual Meeting for Sept. 3, Urges Proxy Votes

TL;DR

**REPL's virtual annual meeting on Sept 3rd is a must-vote for shareholders to shape the company's future, don't just sit on your hands!**

AI Summary

Replimune Group, Inc. (REPL) filed a DEF 14A proxy statement on July 25, 2025, for its Annual Meeting of Stockholders scheduled for September 3, 2025, at 11:30 a.m. Eastern Time. The meeting will be entirely virtual, accessible via www.meetnow.global/MF6VJVT. The proxy materials, including the Annual Report for the fiscal year ended March 31, 2025, were first sent to stockholders around July 25, 2025. Stockholders of record as of July 16, 2025, are eligible to vote on the matters described in the Proxy Statement. The filing emphasizes the importance of stockholder participation and voting, even if not attending the virtual meeting. Specific financial figures for revenue and net income are not detailed in this DEF 14A, as it primarily outlines the procedural aspects of the upcoming annual meeting and voting process. Key business changes, risks, and strategic outlook are typically covered in the accompanying Annual Report, which is referenced but not summarized here.

Why It Matters

This DEF 14A filing is crucial for Replimune investors as it outlines the procedural framework for the 2025 Annual Meeting, where key corporate governance decisions will be made. Investor participation in voting on board elections, executive compensation, and other proposals directly impacts the company's strategic direction and accountability. For employees and customers, the outcomes of these votes can influence long-term stability and operational focus. In the competitive biotech landscape, strong governance and clear investor mandates are vital for Replimune to maintain investor confidence and pursue its biological product development, especially against rivals in the oncology space.

Risk Assessment

Risk Level: low — The risk level is low because this DEF 14A filing is a standard procedural document for an annual meeting, primarily detailing logistics like the September 3, 2025 meeting date and the July 16, 2025 record date. It does not contain new financial disclosures or significant operational changes that would introduce immediate market risk. The filing simply informs stockholders about their voting rights and the virtual meeting format.

Analyst Insight

Investors should carefully review the full Proxy Statement and the Annual Report for the fiscal year ended March 31, 2025, which were sent around July 25, 2025. It is imperative to cast your vote on all proposals by the September 3, 2025 meeting date, even if not attending the virtual meeting, to ensure your voice is heard on corporate governance matters.

Key Players & Entities

• Replimune Group, Inc. (company) — Registrant and issuer of the DEF 14A
• September 3, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
• July 16, 2025 (date) — Record date for stockholders entitled to vote at the Annual Meeting
• July 25, 2025 (date) — Date the Notice of Internet Availability of Proxy Materials was first sent
• Woburn, MA (location) — Business address of Replimune Group, Inc.
• 500 Unicorn Park Drive Suite 303 (location) — Street address of Replimune Group, Inc.
• 11:30 a.m., Eastern Time (time) — Scheduled start time of the Annual Meeting
• www.meetnow.global/MF6VJVT (website) — Virtual meeting platform for the Annual Meeting
• March 31, 2025 (date) — End of the fiscal year for the Annual Report referenced
• SEC (regulator) — United States Securities and Exchange Commission

FAQ

Industry Context

Replimune Group operates in the biotechnology sector, specifically focusing on the development of oncolytic immunotherapies. This is a highly competitive and rapidly evolving field driven by scientific innovation and significant R&D investment. Key trends include advancements in gene editing, personalized medicine, and the increasing focus on combination therapies to enhance treatment efficacy.

Regulatory Implications

As a biotechnology company, Replimune is subject to stringent regulatory oversight from bodies like the FDA. Approval processes for new therapies are lengthy and complex, with potential delays or rejections posing significant risks. Compliance with evolving clinical trial regulations and manufacturing standards is critical for continued operation and product development.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-07-25: Proxy materials (DEF 14A and Annual Report) first sent to stockholders. — Informs shareholders about the upcoming annual meeting and provides information for voting.
• 2025-07-16: Record date for determining stockholders entitled to vote. — Establishes the list of shareholders who have the right to vote at the Annual Meeting.
• 2025-09-03: 2025 Annual Meeting of Stockholders. — The date for the virtual meeting where key company matters will be voted upon by shareholders.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC, providing detailed information about matters to be voted on at a company's annual meeting. (This is the primary document filed by Replimune, outlining the agenda and voting procedures for their annual shareholder meeting.)

Proxy Statement

A document that the SEC requires companies to provide to shareholders before their annual meeting, containing information about the meeting agenda, board nominees, executive compensation, and other relevant business. (This document guides shareholders on how to vote and what to expect at the Replimune annual meeting.)

Annual Report

A comprehensive report on a company's activities throughout the preceding year, including financial statements and management's discussion and analysis. (Provides detailed financial and operational performance information for the fiscal year ended March 31, 2025, referenced in the proxy statement.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (July 16, 2025, is the record date for Replimune, meaning only shareholders who owned stock on this date can vote.)

Year-Over-Year Comparison

This DEF 14A filing for the 2025 Annual Meeting focuses on procedural aspects and voting matters, referencing the Annual Report for detailed financial performance. Specific comparative financial metrics like revenue growth or margin changes from the prior fiscal year are not detailed within this proxy statement itself. Investors should refer to the accompanying Annual Report for a comprehensive year-over-year financial comparison and analysis of business risks and strategic developments.

From the Filing

0001104659-25-070833.txt : 20250725 0001104659-25-070833.hdr.sgml : 20250725 20250725161604 ACCESSION NUMBER: 0001104659-25-070833 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250903 FILED AS OF DATE: 20250725 DATE AS OF CHANGE: 20250725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 251151873 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 DEF 14A 1 tm2521674-1_def14a.htm DEF 14A tm2521674-1_nonfiling - none - 7.9687539s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ​ ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​ ☒ Definitive Proxy Statement ​ ☐ Definitive Additional Materials ​ ☐ Soliciting Material under §240.14a-12 ​ REPLIMUNE GROUP, INC. ​ (Name of Registrant as Specified In Its Charter) ​ ​ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) ​ Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ​ ☐ Fee paid previously with preliminary materials. ​ ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11 ​ TABLE OF CONTENTS Replimune Group, Inc. 500 Unicorn Park Drive Suite 303 Woburn, MA 01801 Dear Stockholders: On behalf of the Board of Directors of Replimune Group, Inc. (the “Company,” “we” or “Replimune”), I invite you to attend our 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which will be held on Wednesday, September 3, 2025, at 11:30 a.m., Eastern Time. The Annual Meeting will be a completely virtual meeting of stockholders conducted via live webcast. You will be able to participate in the Annual Meeting, vote online during the Annual Meeting and submit your questions during the Annual Meeting by visiting www.meetnow.global/MF6VJVT , but you will not be able to attend the Annual Meeting in person. A Notice of Internet Availability of Proxy Materials, which contains instructions on how to access online the proxy statement accompanying this letter (the “Proxy Statement”) and our Annual Report for the fiscal year ended March 31, 2025, is first being sent to stockholders on or about July 25, 2025. We urge you to carefully read our proxy materials, which provide important information about the Annual Meeting and will serve as your guide to the business that will be conducted at the Annual Meeting. The matters to be voted upon at the Annual Meeting are listed in the Notice of 2025 Annual Meeting of Stockholders and are more fully described in the Proxy Statement. All holders of record of our common stock at the close of business on July 16, 2025, the record date, are entitled to notice of and to vote at the Annual Meeting and any continuation, postponement, or adjournment thereof. Whether or not you participate in the Annual Meeting, it is important that your shares be represented and voted during the Annual Meeting. We therefore are soliciting proxies so that each stockholder has an opportunity to vote on the matters that are schedule